Use access key #2 to skip to page content.
$5.71 -0.19 (-3.22%)
9/4/2008 4:00 PM

Exelixis, Inc. (EXEL)

CAPS Rating:
*****

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

View All Commentary (EXEL)

Recs

1

Avatar LeoFender (< 20) Submitted: 8/18/06 6:30 PM : Outperform Start Price: $8.48 EXEL Score: -28.07

With solid results in the pipeline, EXEL seems poised to post profit around 2010.

Report this Post Replies: 1 | Reply

Avatar LeoFender (< 20) Submitted: 9/23/06 1:39 PM

Recs: 0 | Rec This

I'm RAISING my fair value estimate from 10 dollars per share to 11. Most Fools are investing in the pipeline and the patents. This is a good reason to invest, however, the PLATFORM is already starting to show it's strength. Developing NEW drugs gives the company further value, and makes it a more solid long term play.

I still don't see profit for this small company until 2010, but now I'm raising my growth estimates as well as overall value of the platform.

Report this Post Reply

Featured Broker Partners